Term ends Nov 24, 2030 · Medium confidence
20-year base term ends Nov 24, 2030
Why Medium: A parent in the chain could not be resolved.
Held by MedImmune Limited
Filed Jul 23, 2019 as application 16/519,614 · Granted Dec 6, 2022
Base term, 20 years from filing
Today
2010
2030
Clock starts
Nov 24, 2010
Nov 24, 2010
Term ends
Nov 24, 2030
Nov 24, 2030
Granted
Dec 6, 2022
Dec 6, 2022
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,400,039, US 8,779,108, to Nov 24, 2030. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 24, 2010, when application PCT/US2010/058007, the earliest non-provisional in its chain, was filed (this one was filed Jul 23, 2019); a parent in its chain could not be resolved (the next row) | Nov 24, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,400,039, US 8,779,108) | resolves to Nov 24, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 24, 2030 | Medium confidence |
This family
| US 8,779,108 | In force Nov 2030 | Nov 2030 |
| US 9,493,565 | In force May 2031 | May 2031 |
| US 10,400,039 | In force Nov 2030 | Nov 2030 |
| US 11,518,809 | this patent Nov 2030 | Nov 2030 |
| US 12,686,718 | In force Jun 2031 | Jun 2031 |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 25, 2019 Reel 49861, frame 934 | Hammond, Scott; Mulgrew, Kathleen Ann | MedImmune, LLC | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49870, frame 349 | Queva, Christophe; Babcock, John; Foltz, Ian Nevin; Kang, Jaspal Singh; Sekirov, Laura | Amgen British Columbia | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49862, frame 415 | Morrow, Michelle; Boyle, Melanie; Chodorge, Matthieu; Stewart, Ross A. | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49862, frame 550 | Alimzhanov, Marat | AstraZeneca AB | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49862, frame 700 | Amgen British Columbia | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49862, frame 939 | AstraZeneca AB | MedImmune Limited | Assignment of Assignor's Interest |
| Jul 25, 2019 Reel 49871, frame 832 | MedImmune, LLC | MedImmune Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2030
Term ends Nov 24, 2030. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,400,039, US 8,779,108, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.